Biotech · Private company · Hayward, CA, US
Impax Laboratories, LLC
SEC CIK 0001003642
Track this companyFree. Adds Impax Laboratories, LLC to your Dealase workspace and tells you when its record changes.
Clinical trials191 recruiting or active
Pipeline programs40From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline40
- CLEPhase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Encapsulated Baclofen 20 mgPhase 3 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- IPX056 10 mgPhase 3 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- IPX056 20 mgPhase 3 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- IPX056 30 mgPhase 3 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- IPX056 40 mgPhase 3 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- IPX066Phase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX066 145 mgPhase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX066 145 mg LDPhase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX066 195 mgPhase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX066 195 mg LDPhase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX066 245 mgPhase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX066 245 mg LDPhase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX066 95 mgPhase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX066 95 mg LDPhase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX203Phase 3 · Parkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX203 ER CD-LDPhase 3 · Parkinson's Disease (Disorder)ClinicalTrials.gov · fetched Nov 12, 2026
- IR CD-LDPhase 3 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IR CD-LDPhase 3 · Parkinson's Disease (Disorder)ClinicalTrials.gov · fetched Nov 12, 2026
- ZNSPhase 3 · MigraineClinicalTrials.gov · fetched Nov 12, 2026
- Baclofen IRPhase 2 · SpasticityClinicalTrials.gov · fetched Nov 12, 2026
- CD-LD CRPhase 2 · Idiopathic Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- CD-LD IRPhase 2 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- CD-LD IRPhase 2 · Idiopathic Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX054 100 mgPhase 2 · Idiopathic Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX054 150 mgPhase 2 · Idiopathic Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX054 200 mgPhase 2 · Idiopathic Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX054 200 mgPhase 2 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX054 250 mgPhase 2 · Idiopathic Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX054 300 mgPhase 2 · Idiopathic Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX056Phase 2 · SpasticityClinicalTrials.gov · fetched Nov 12, 2026
- IPX203Phase 2 · Advanced Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX203 180 mgPhase 2 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- IPX203 270 mgPhase 2 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Rytary 145 mgPhase 2 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Rytary 195 mgPhase 2 · Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- SinemetPhase 2 · Advanced Parkinson's DiseaseClinicalTrials.gov · fetched Nov 12, 2026
- Carbidopa capsulePhase 1 · Cardiac Repolarization in Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- Moxifloxacin Tablets, USPPhase 1 · Cardiac Repolarization in Healthy SubjectsClinicalTrials.gov · fetched Nov 12, 2026
- CREXONT ERParkinson DiseaseClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials19
- A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's DiseasePHASE4 · RECRUITING · started Feb 12, 2025ClinicalTrials.gov NCT06765668 · fetched Nov 12, 2026
- A TQT Study to Evaluate the Electrocardiographic Effects of Carbidopa in Healthy SubjectsPHASE1 · COMPLETED · started Oct 30, 2023ClinicalTrials.gov NCT06161220 · fetched Nov 12, 2026
- Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor FluctuationsPHASE3 · COMPLETED · started Apr 3, 2019ClinicalTrials.gov NCT03877510 · fetched Nov 12, 2026
- A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor FluctuationsPHASE3 · COMPLETED · started Nov 6, 2018ClinicalTrials.gov NCT03670953 · fetched Nov 12, 2026
- Efficacy & Safety Of Zomig Nasal Spray For Acute Migraine Treatment In Subjects 6 To 11 Years, With OLEPHASE3 · COMPLETED · started Nov 27, 2017ClinicalTrials.gov NCT03275922 · fetched Nov 12, 2026
- A Study to Assess the PK and Pharmacodynamics of IPX203 in Subjects With Advanced Parkinson's DiseasePHASE2 · COMPLETED · started Nov 14, 2016ClinicalTrials.gov NCT03007888 · fetched Nov 12, 2026
- Comparative Safety and Efficacy of Two Treatments in the Treatment of Vulvar and Vaginal AtrophyPHASE3 · COMPLETED · started May 1, 2016ClinicalTrials.gov NCT02770365 · fetched Nov 12, 2026
- A Study to Assess the PK and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson's DiseasePHASE2 · COMPLETED · started Nov 1, 2015ClinicalTrials.gov NCT02271503 · fetched Nov 12, 2026
- Carbidopa-Levodopa (CD-LD) ER Alone or in Combination With CD-LD IR to IPX066 Followed by IPX066 Extension Safety StudyPHASE3 · COMPLETED · started Aug 1, 2011ClinicalTrials.gov NCT01411137 · fetched Nov 12, 2026
- A Study to Compare IPX066 and Carbidopa/Levodopa/Entacapone (CLE) Followed by an Open-Label Safety Study of IPX066PHASE3 · COMPLETED · started May 1, 2010ClinicalTrials.gov NCT01130493 · fetched Nov 12, 2026
- An Open Label Extension Study of the Safety and Clinical Utility of IPX066 in Subjects With Parkinson's DiseasePHASE3 · COMPLETED · started Mar 1, 2010ClinicalTrials.gov NCT01096186 · fetched Nov 12, 2026
- A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease (ADVANCE-PD).PHASE3 · COMPLETED · started Sep 1, 2009ClinicalTrials.gov NCT00974974 · fetched Nov 12, 2026
- A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's DiseasePHASE3 · COMPLETED · started Apr 1, 2009ClinicalTrials.gov NCT00880620 · fetched Nov 12, 2026
- A Study With IPX056 in Subjects With Spasticity Associated With Multiple SclerosisPHASE2 · COMPLETED · started Apr 1, 2009ClinicalTrials.gov NCT00914290 · fetched Nov 12, 2026
- A Study to Compare Pharmacokinetics and Pharmacodynamics of IPX066 to Standard Carbidopa-LevodopaPHASE2 · COMPLETED · started Nov 1, 2008ClinicalTrials.gov NCT00869791 · fetched Nov 12, 2026
- IPX056 in Subjects With Established Spasticity Resulting From Multiple SclerosisPHASE3 · COMPLETED · started Jun 1, 2007ClinicalTrials.gov NCT00488839 · fetched Nov 12, 2026
- Comparison of IPX054, IR Carbidopa-Levodopa, and CR Carbidopa-Levodopa in Subjects With Parkinson's DiseasePHASE2 · COMPLETED · started Jan 1, 2006ClinicalTrials.gov NCT00279825 · fetched Nov 12, 2026
- Comparison of IPX054 and Immediate-Release Carbidopa-Levodopa in Patients With Parkinson's DiseasePHASE2 · COMPLETED · started Nov 1, 2005ClinicalTrials.gov NCT00253084 · fetched Nov 12, 2026
- Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's DiseasePHASE1_PHASE2 · COMPLETED · started Oct 1, 2005ClinicalTrials.gov NCT00239564 · fetched Nov 12, 2026